Lymphangiogenesis and hemangiogenesis: Potential targets for therapy

Journal of Surgical Oncology

Volumn 103, Issue 6, 2011, Pages 489-500

  Witte, Marlys H ^a   Dellinger, Michael T ^b   McDonald, Donald M ^c   Nathanson, S David ^d   Boccardo, Francesco M ^e   Campisi, Corradino C C ^e   Sleeman, Jonathan P ^f,g   Gershenwald, Jeffrey E ^h  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF GENOA   (Italy)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g Karlsruhe Institut für Toxikologie und Genetik   (Germany)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

angiogenesis; anti lymphangiogenesis; lymphatic development; lymphogenous cancer spread

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; FIBROBLAST GROWTH FACTOR 2; PLATELET DERIVED GROWTH FACTOR BB; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D;

BREAST CANCER; CANCER INVASION; CANCER THERAPY; HUMAN; LYMPHANGIOGENESIS; METASTASIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE BIOPSY; TUMOR CELL;

ANGIOGENESIS INHIBITORS; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 79953854809     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21714     Document Type: Review

References (108)

1. Witte MH, Way DL, Witte CL, et al.: Lymphangiogenesis: Mechanisms, significance and clinical implications. In:, Goldberg ID, Rosen EM, editors. Regulation of angiogenesis. Basel, Switzerland: Birkhauser Verlag; 1997. pp 65-112.
2. Folkman J,: Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
3. Joukov V, Pajusola K, Kaipanen A, et al.: A novel vascular endothelial growth factor, VEGFC, is a ligand for the Flt 4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996; 15: 1951 [Erratum for EMBO J 1996; 15:290-298].
4. Karkkainen MJ, Ferrell RE, Lawrence EC, et al.: Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet 2000; 25: 153-159. (Pubitemid 30394984)
5. Fang JM, Dagenais SL, Erickson RP, et al.: Mutations in Foxc2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am J Hum Genet 2000; 67: 1382-1388.
6. Irrthum A, Devriendt K, Chitayat D, et al.: Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia. Am J Hum Genet 2003; 72: 1470-1478. (Pubitemid 36628386)
7. Dellinger M, Bernas M, Witte M,: Lymphatic biology and pathobiology. In:, Dieter R, Dieter RA, Jr., Dieter RA III, editors. Venous and lymphatic disorders, Chapter 3. New York, NY: McGraw Hill (in press).
8. Gale NW, Thurston G, Hackett SF, et al.: Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell 2002; 3: 411-423.
9. Stacker S, Caesar C, Baldwin M, et al.: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001; 7: 186-191. (Pubitemid 32148485)
10. Alders M, Hogan BM, Gjini E, et al.: Mutations in CCBE1 cause generalized lymph vessel dysplasia in humans. Nat Genet 2009; 41: 1272-1274.
11. Connell F, Kalidas K, Ostergaard P, et al.: Lymphoedema Consortium. Linkage and sequence analysis indicate that CCBE1 is mutated in recessively inherited generalised lymphatic dysplasia. Hum Genet 2010; 127: 231-241 [Erratum appears in Hum Genet 2010; 127:243].
12. Ferrell RE, Baty CJ, Kimak MA, et al.: GJC2 missense mutations cause human lymphedema. Am J Hum Genet 2010; 86: 943-948.
13. Witte MH, Dellinger M, Bernas MJ, et al.: Molecular lymphology and genetics of lymphedema-angiodysplasia syndromes. In:, Földi M, Földi E, editors. Textbook of lymphology, 3rd edition, Chapter 16. München, Germany: Urban & Fischer Verlag; 2010 (in press).
14. Brown P,: Unlocking the drains. Nature 2005; 436: 456-458.
15. Witte MH, Ohkuma M, Andrade M, et al.: Nature's historic gap: The 20th century of lymphology. Lymphology 2005; 38: 157-158. (Pubitemid 43165432)
16. Sabin FR,: On the origin and development of the lymphatic system from the veins and the development of the lymph hearts and the thoracic duct in the pig. Am J Anat 1902; 1: 367-389.
17. Kampmeier OF,: Evolution and comparative morphology of the lymphatic system. Springfield, IL: Charles C. Thomas; 1969.
18. XI-XXII International Congress of Lymphology Proceedings. Lymphology (suppl) 1987-2009; 27-42.
19. Witte M, Witte C,: On tumor (and other) lymphangiogenesis. Lymphology 1997; 30: 1-2. (Pubitemid 27171301)
20. Witte MH, Jones K, Wilting J, et al.: Structure-function relationships in the lymphatic system and implications for cancer biology. Cancer Metastasis Rev 2006; 25: 159-184. (Pubitemid 43886395)
21. Fisher B, Fisher ER,: The interrelationship of hematogenous and lymphatic tumor cell dissemination. Surg Gynecol Obstet 1966; 122: 791-798.
22. Azzali G,: Tumor cell transendothelial passage in the absorbing lymphatic vessel of transgenic adenocarcinoma mouse prostate. Am J Pathol 2007; 170: 334-346. (Pubitemid 47339211)
23. Witte MH, Bernas MJ, Martin CP, et al.: Lymphangiogenesis and lymphangiodysplasia: From molecular to clinical lymphology. In: J. Wilting, guest editor. The biology of lymphangiogenesis. Microsc Res Tech 2001; 55: 122-145. (Pubitemid 32988912)
24. Sabin FR,: On the development of the superficial lymphatics in the skin of the pig. Am J Anat 1904; 3: 183-195.
25. Sabin FR,: The lymphatic system in human embryos, with a consideration of the morphology of the system as a whole. Am J Anat 1909; 9: 43-91.
26. Kampmeier OF,: The development of the thoracic duct in the pig. Am J Anat 1912; 13: 401-475.
27. McClure CFW,: A few remarks relative to Mr. Kampmeier's paper on "The value of the injection method in the study of lymphatic development." Anat Rec 1912; 6: 233-246.
28. Kampmeier OF,: The value of the injection method in the study of lymphatic development. Anat Rec 1912; 6: 223-232.
29. Sabin FR,: A critical study of the evidence presented in several recent articles on the development of the lymphatic system. Anat Rec 1911; 5: 417-446.
30. Wigle JT, Oliver G,: Prox1 function is required for the development of the murine lymphatic system. Cell 1999; 98: 769-778. (Pubitemid 29446894)
31. Wigle JT, Harvey N, Detmar M, et al.: An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J 2002; 21: 1505-1513. (Pubitemid 34614607)
32. Francois M, Caprini A, Hosking B, et al.: Sox18 induces development of the lymphatic vasculature in mice. Nature 2008; 456: 643-647.
33. Karkkainen MJ, Haiko P, Sainio K, et al.: Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 2004; 5: 74-80. (Pubitemid 38081471)
34. Wilting J, Aref Y, Huang R, et al.: Dual origin of avian lymphatics. Dev Biol 2006; 292: 165-173.
35. Ny A, Koch M, Schneider M, et al.: A genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nat Med 2005; 11: 998-1004. (Pubitemid 41294447)
36. Srinivasan RS, Dillard ME, Lagutin OV, et al.: Lineage tracing demonstrates the venous origin of the mammalian lymphatic vasculature. Genes Dev 2007; 21: 2422-2432. (Pubitemid 47529372)
37. Kerjaschki D, Huttary N, Raab I, et al.: Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. Nat Med 2006; 12: 230-234. (Pubitemid 43214751)
38. Jiang S, Bailey A, Goldman DC, et al.: Hematopoietic stem cells contribute to lymphatic endothelium. PLoS ONE 2008; 3: e3812.
39. Zumsteg A, Baeriswyl V, Imaizumi N, et al.: Myeloid cells contribute to tumor lymphangiogenesis. PLoS ONE 2009; 4: e7067.
40. Clark ER,: Observations on living growing lymphatics in the tail of frog larva. Anat Rec 1909; 3: 183-198.
41. Clark ER, Clark EL,: Observations on the new growth of lymphatic vessels as seen in transparent chambers introduced into the rabbit's ear. Am J Anat 1932; 51: 49-87.
42. Oh SJ, Jeltsch MM, Birkenhäger R, et al.: VEGF and VEGF-C: Specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol 1997; 188: 96-109. (Pubitemid 27360090)
43. Jeltsch M, Kaipainen A, Joukov V, et al.: Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997; 276: 1423-1425. (Pubitemid 27235412)
44. Dellinger MT, Hunter RJ, Bernas MJ, et al.: Chy-3 mice are Vegfc haploinsufficient and exhibit defective dermal superficial to deep lymphatic transition and dermal lymphatic hypoplasia. Dev Dyn 2007; 236: 2346-2355. (Pubitemid 47293777)
45. Karkkainen MJ, Saaristo A, Jussila L, et al.: A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci USA 2001; 98: 12677-12682. (Pubitemid 33020005)
46. Bjorndahl M, Cao R, Nissen LJ, et al.: Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci USA 2005; 102: 15593-15598. (Pubitemid 41528101)
47. Cao R, Bjorndahl MA, Religa P, et al.: PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 2004; 6: 333-345. (Pubitemid 39361435)
48. Kajiya K, Hirakawa S, Ma B, et al.: Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J 2005; 24: 2885-2895. (Pubitemid 43079892)
49. Kubo H, Cao R, Brakenhielm E, et al.: Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci USA 2002; 99: 8868-8873. (Pubitemid 34693650)
50. Morisada T, Oike Y, Yamada Y, et al.: Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood 2005; 105: 4649-4656. (Pubitemid 40807284)
51. Tammela T, Saaristo A, Lohela M, et al.: Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood 2005; 105: 4642-4648. (Pubitemid 40807283)
52. Veikkola T, Jussila L, Mäkinen T, et al.: Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 2001; 20: 1223-1231. (Pubitemid 32233963)
53. Oliver G, Srinivasan RS,: Endothelial cell plasticity: How to become and remain a lymphatic endothelial cell. Development 2010; 137: 363-372.
54. Kriederman BM, Myloyde TL, Witte MH, et al.: FOXC2 haploinsufficient mice are a model for human autosomal dominant lymphedema-distichiasis syndrome. Hum Mol Genet 2003; 12: 1179-1185. (Pubitemid 36622150)
55. Petrova TV, Karpanen T, Norrmén C, et al.: Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat Med 2004; 10: 974-981. (Pubitemid 39273739)
56. Norrmén C, Ivanov KI, Cheng J, et al.: FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. J Cell Biol 2009; 185: 439-457.
57. Bazigou E, Xie S, Chen C, et al.: Integrin-alpha9 is required for fibronectin matrix assembly during lymphatic valve morphogenesis. Dev Cell 2009; 17: 175-186.
58. Kampmeier OF,: Further observations on the numerical variability, position, function and fate of the valves in the human thoracic duct. Anat Rec 1928; 38: 225-231.
59. Mäkinen T, Adams RH, Bailey J, et al.: PDZ interaction site in ephrinb2 is required for the remodeling of lymphatic vasculature. Genes Dev 2005; 19: 397-410. (Pubitemid 40189302)
60. Dellinger M, Hunter R, Bernas M, et al.: Defective remodeling and maturation of the lymphatic vasculature in angiopoietin-2 deficient mice. Dev Biol 2008; 319: 309-320.
61. Baluk P, Fuxe J, Hashizume H, et al.: Functionally specialized junctions between endothelial cells of lymphatic vessels. J Exp Med 2007; 204: 2349-2362. (Pubitemid 47529321)
62. Dejana E, Orsenigo F, Molendini C, et al.: Organization and signaling of endothelial cell-to-cell junctions in various regions of the blood and lymphatic vascular trees. Cell Tissue Res 2009; 335: 17-25.
63. Fidler IJ, Baker CH, Yokoi K, et al.: Targeting the tumor microenvironment for treatment of metastasis. In:, Figg WD, Folkman J, editors. Angiogenesis: An integrative approach from science to medicine. New York: Springer; 2008. pp 259-270.
64. Liotta LA, Kleinerman J, Saidel GM,: Quantitative relationships of intravascular tumor cells, tumor vessels and pulmonary metastases following tumor implantation. Cancer Res 1974; 34: 997-1004.
65. Halsted W,: The results of operations for the cure of carcinoma of the breast. Ann Surg 1907; 46: 1-9.
66. Hellman S,: Karnovsky Memorial Lecture. Natural history of small breast cancers. J Clin Oncol 1994; 12: 2229-2234. (Pubitemid 24356043)
67. Nathanson SD,: Insights into the mechanisms of lymph node metastasis. Cancer 2003; 98: 413-423. (Pubitemid 36828469)
68. Hoshida T, Isaka N, Hagendoorn J, et al.: Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: Therapeutic implications. Cancer Res 2006; 66: 8065-8075. (Pubitemid 44299172)
69. Mohammed RAA, Martin SG, Gill MS, et al.: Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. Am J Surg Pathol 2007; 31: 1825-1833. (Pubitemid 350175809)
70. Nathanson SD, Westrick P, Anaya P, et al.: Relationship of spontaneous regional lymph node metastases to dose of local irradiation of primary B16 melanomas. Cancer Res 1989; 49: 4412-4416. (Pubitemid 19208335)
71. Reintgen D, Cruse CW, Wells K,: The orderly progression of melanoma nodal metastases. Ann Surg 1994; 220: 759-767. (Pubitemid 24376374)
72. Nathanson SD, Kwon D, Kapke A, et al.: The role of lymph node metastasis in the systemic dissemination of breast cancer. Ann Surg Oncol 2009; 16: 3396-3405.
73. Nathanson SD, Nelson LT,: Interstitial fluid pressure in breast cancer, benign breast conditions and breast parenchyma. Ann Surg Oncol 1994; 1: 333-338.
74. Padera TP, Stoll BR, Tooredman JB, et al.: Pathology: Cancer cells compress intratumour vessels. Nature 2004; 427: 695. (Pubitemid 38294577)
75. Thompson M, Korourian S, Henry-Tillman R, et al.: Axillary reverse mapping (ARM): A new concept to identify and enhance lymphatic preservation. Ann Surg Oncol 2007; 14: 1890-1895. (Pubitemid 46870948)
76. Sakorafasa GH, Perosa G, Cataliotti L, et al.: Lymphedema following axillary lymph node dissection for breast cancer. Surg Oncol 2006; 15: 153-165. (Pubitemid 46241869)
77. Nos C, Lesieur B, Clough KB, et al.: Blue dye injection in the arm in order to conserve the lymphatic drainage of the arm in breast cancer patients requiring an axillary dissection. Ann Surg Oncol 2007; 14: 2490-2496. (Pubitemid 47389579)
78. Ponzone R, Mininanni P, Cassina E, et al.: Axillary reverse mapping in breast cancer: Can we spare what we find? Ann Surg Oncol 2007; 15: 390-391.
79. Jila A, Kim H, Nguyen VP, et al.: Lymphangiogenesis following obstruction of large postnodal lymphatics in sheep. Microvasc Res 2007; 73: 214-223. (Pubitemid 46601520)
80. Modi S, Stanton AWB, Svensson WE, et al.: Human lymphatic pumping measured in healthy and lymphoedematous arms by lymphatic congestion lymphoscintigraphy. J Physiol 2007; 583: 271-285. (Pubitemid 47244258)
81. Boccardo F, Casabona F, De Cian F, et al.: Lymphedema microsurgical preventive healing approach: A new technique for primary prevention of arm lymphedema after mastectomy. Ann Surg Oncol 2009; 16: 703-708.
82. Karpanen T, Alitalo K,: Molecular biology and pathology of lymphangiogenesis. Annu Rev Pathol 2008; 3: 367-397. (Pubitemid 351488286)
83. Sleeman J, Thiele W,: Tumor metastasis and the lymphatic vasculature. Int J Cancer 2009; 125: 2747-2756.
84. Sleeman J, Schmid A, Thiele W,: Tumor lymphatics. Semin Cancer Biol 2009; 19: 285-297.
85. Krishnan J, Kirkin V, Steffen A, et al.: Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res 2003; 63: 713-722. (Pubitemid 36158152)
86. Iwata C, Kano MR, Komuro A, et al.: Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res 2007; 67: 10181-10189. (Pubitemid 350070790)
87. Shibata MA, Morimoto J, Shibata E, et al.: Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model. Cancer Gene Ther 2008; 15: 776-786.
88. Hirakawa S, Kodama S, Kunstfeld R, et al.: VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 2005; 201: 1089-1099. (Pubitemid 40524677)
89. Hirakawa S, Brown LF, Kodama S, et al.: VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 2007; 109: 1010-1017. (Pubitemid 46220646)
90. Harrell MI, Iritani BM, Ruddell A,: Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am J Pathol 2007; 170: 774-786. (Pubitemid 47339411)
91. Ruddell A, Kelly-Spratt KS, Furuya M, et al.: p19/Arf and p53 suppress sentinel lymph node lymphangiogenesis and carcinoma metastasis. Oncogene 2008; 27: 3145-3155. (Pubitemid 351693168)
92. Van den Eynden GG, Van der Auwera I, Van Laere SJ, et al.: Induction of lymphangiogenesis in and around axillary lymph node metastases of patients with breast cancer. Br J Cancer 2006; 95: 1362-1366. (Pubitemid 44760086)
93. Wang TB, Deng MH, Qiu WS, et al.: Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J Gastroenterol 2007; 13: 1794-1797, discussion 1797-1798.
94. Yu XM, Lo CY, Lam AK, et al.: Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma. Ann Surg 2008; 247: 483-489.
95. Spring H, Schuler T, Arnold B, et al.: Chemokines direct endothelial progenitors into tumor neovessels. Proc Natl Acad Sci USA 2005; 102: 18111-18116. (Pubitemid 41798510)
96. Kirkin V, Mazitschek R, Krishnan J, et al.: Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2. Eur J Biochem 2001; 268: 5530-5540. (Pubitemid 34183319)
97. Kirkin V, Thiele W, Baumann P, et al.: MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo. Int J Cancer 2004; 112: 986-993. (Pubitemid 39507004)
98. Schempp CM, Kirkin V, Simon-Haarhaus B, et al.: Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis. Oncogene 2002; 21: 1242-1250. (Pubitemid 34185241)
99. Schempp CM, Kiss J, Kirkin V, et al.: Hyperforin acts as an angiogenesis inhibitor. Planta Med 2005; 71: 999-1004.
100. Rothley M, Schmid A, Thiele W, et al.: Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress tumor-induced lymphangiogenesis in vivo. Int J Cancer 2009; 125: 34-42.
101. Gartner M, Muller T, Simon JC, et al.: Aristoforin, a novel stable derivative of hyperforin, is a potent anticancer agent. ChemBioChem 2005; 6: 171-177. (Pubitemid 40128650)
102. Bruyère F, Melen-Lamalle L, Blacher S, et al.: Modeling lymphangiogenesis in a three-dimensional culture system. Nat Methods 2008; 5: 431-437. (Pubitemid 351619102)
103. Teller N, Thiele W, Boettler U, et al.: Delphinidin inhibits a broad spectrum of receptor tyrosine kinases of the ErbB and VEGFR family. Mol Nutr Food Res 2009; 53: 1075-1083.
104. Teller N, Thiele W, Marczylo TH, et al.: Suppression of the kinase activity of receptor tyrosine kinases by anthocyanin-rich mixtures extracted from bilberries and grapes. J Agric Food Chem 2009; 57: 3094-3101.
105. Fidler J,: Clinical oncology, 2nd edition. New York: Churchill Livingstone; 2000. pp 29-53.
106. Gershenwald JE, Fidler IJ,: Cancer. Targeting lymphatic metastasis. Science 2002; 296: 1811-1812.
107. Foster RS, Jr.:, General anatomy of the lymphatic system. Surg Oncol Clin N Am 1996; 5: 1-13. (Pubitemid 26047379)
108. Gershenwald JE, Thompson W, Mansfield PF, et al.: Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17: 976-983. (Pubitemid 29109331)